Glioma
Conditions
Interventions
Gliomas:None
Non-gliomas:None
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Analysis of genetic markers for the diagnosis of glioma patients (1) Registered on the NBTRC platform from January 2020 to December 2023; (2) Pathologically diagnosed with glioma after surgery; (3) Complete molecular pathological test results available, at least including IDH1/2, TERTp, 1p/19q, MGMT, EGFR, TP53, ATRX, CIC, FUBP1, etc.; 2. Analysis of genetic markers for the prognosis of glioma patients (1) Registered on the NBTRC platform from January 2020 to December 2023; (2) Pathologically diagnosed with glioma after surgery; (3) Complete molecular pathological test results available, at least including IDH1/2, TERTp, 1p/19q, MGMT, EGFR, TP53, ATRX, CIC, FUBP1, etc.; (4) Completed 3 years of follow-up; 3. Retrospective cohort study (1) Not diagnosed with glioma at baseline, with imaging abnormalities only allowed; (2) Genetic marker test results from preoperative blood or cerebrospinal fluid samples available, such as cfDNA, ctDNA, mutation panel; (3) Clear follow-up records available to determine whether glioma was subsequently diagnosed; 4. Nested case-control study (1) Registered on the NBTRC platform from January 2020 to December 2023; (2) Pathologically diagnosed with glioma after surgery; (3) Complete molecular pathological test results available, at least including IDH1/2, TERTp, 1p/19q, MGMT, EGFR, TP53, ATRX, CIC, FUBP1, etc.; (4) Completed 3 years of follow-up; 5. Survival analysis (1) Registered on the NBTRC platform from January 2020 to December 2023; (2) Pathologically diagnosed with glioma after surgery; (3) Complete molecular pathological test results available, at least including IDH1/2, TERTp, 1p/19q, MGMT, EGFR, TP53, ATRX, CIC, FUBP1, etc.; (4) Completed 3 years of follow-up.
Exclusion criteria
Exclusion criteria: 1. Analysis of genetic markers for the diagnosis of glioma patients (1) Patients with other intracranial tumors or metastatic tumors were excluded; (2) Participants who explicitly indicated in the informed consent form that they did not agree to the use of their clinical data for subsequent related research were excluded. 2. Analysis of genetic markers for the prognosis of glioma patients (1) Patients with other intracranial tumors or metastatic tumors were excluded; (2) Participants who explicitly indicated in the informed consent form that they did not agree to the use of their clinical data for subsequent related research were excluded. 3. Retrospective cohort study (1) Patients with a history of intracranial malignant tumors were excluded; (2) Participants who explicitly indicated in the informed consent form that they did not agree to the use of their clinical data for subsequent related research were excluded. 4. Nested case-control study (1) Patients with other intracranial tumors or metastatic tumors were excluded; (2) Participants who explicitly indicated in the informed consent form that they did not agree to the use of their clinical data for subsequent related research were excluded. 5. Survival analysis (1) Patients with other intracranial tumors or metastatic tumors were excluded; (2) Participants who explicitly indicated in the informed consent form that they did not agree to the use of their clinical data for subsequent related research were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Distribution characteristics of diagnostic and prognostic genetic biomarkers in glioma patients;Association strength between diagnostic biomarkers and glioma incidence;Cumulative overall survival rate (OS) at 1, 2, and 3 years;Trend relationship between WHO grade and survival rate; | — |
Countries
China
Contacts
Public ContactXiao Dan
Beijing Tiantan Hospital, Capital Medical University
Outcome results
None listed